Hasil Pencarian - Takashi Seto

Perbaiki Hasil
  1. 1
    Risk Factors for a Second Episode of Hemoptysis

    Risk Factors for a Second Episode of Hemoptysis oleh Nobuhiko Seki, Go Shiozaki, Mayuko Ota, Shuji Ota, Reishi Seki, Takashi Seto, Kazutsugu Uematsu, Kenji Eguchi

    Diterbitkan 2009-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy

    Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy oleh Taichi Matsubara, Shinkichi Takamori, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Takashi Seto, Tatsuro Okamoto

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation

    Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation oleh Shinkichi Takamori, Taichi Matsubara, Takatoshi Fujishita, Kensaku Ito, Ryo Toyozawa, Takashi Seto, Masafumi Yamaguchi, Tatsuro Okamoto

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data

    Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual pa... oleh Yuri Taniguchi, Hiroaki Okamoto, Tsuneo Shimokawa, Tomonari Sasaki, Takashi Seto, Seiji Niho, Yuichiro Ohe, Yusuke Saigusa

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer

    Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer oleh Naoki Haratake, MD, PhD, Toshihiro Misumi, PhD, Takeharu Yamanaka, PhD, Takashi Seto, MD, PhD

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Brain cavernous hemangioma mimicking radiation‐induced necrosis in a patient with non‐small cell lung cancer

    Brain cavernous hemangioma mimicking radiation‐induced necrosis in a patient with non‐small cell lung cancer oleh Shinkichi Takamori, Takashi Seto, Mikako Jinnouchi, Taichi Matsubara, Naoki Haratake, Naoko Miura, Ryo Toyozawa, Masafumi Yamaguchi, Mitsuhiro Takenoyama

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study

    Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Explorato... oleh Yukio Hosomi, Takashi Seto, Makoto Nishio, Koichi Goto, Noboru Yamamoto, Isamu Okamoto, Kosei Tajima, Yusuke Kajihara, Nobuyuki Yamamoto

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC

    Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC oleh Takayasu Kurata, Kazuhiko Nakagawa, Miyako Satouchi, Takashi Seto, Takeshi Sawada, Shirong Han, Masae Homma, Kazuo Noguchi, Naoyuki Nogami

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    A typical carcinoid tumor of the lung presenting with pure persistent ground-glass opacity on high-resolution computed tomography: a case report

    A typical carcinoid tumor of the lung presenting with pure persistent ground-glass opacity on high-resolution computed tomography: a case report oleh Masafumi Yamaguchi, Fumihiko Hirai, Kenichi Taguchi, Ryo Toyozawa, Makoto Edagawa, Shinichiro Shimamatsu, Kaname Nosaki, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose

    Diterbitkan 2017-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation

    Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping m... oleh Shinkichi Takamori, Shinkichi Takamori, Takashi Seto, Masafumi Yamaguchi, Fumihiko Kinoshita, Takatoshi Fujishita, Kensaku Ito, Ryo Toyozawa, Fumihiro Shoji, Tatsuro Okamoto

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study).

    Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study). oleh Shinkichi Takamori, Taro Ohba, Mototsugu Shimokawa, Taichi Matsubara, Naoki Haratake, Naoko Miura, Ryo Toyozawa, Masafumi Yamaguchi, Takashi Seto, Mitsuhiro Takenoyama

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)

    Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study) oleh Shinkichi Takamori, Taro Ohba, Mototsugu Shimokawa, Taichi Matsubara, Naoki Haratake, Naoko Miura, Ryo Toyozawa, Masafumi Yamaguchi, Takashi Seto, Mitsuhiro Takenoyama

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue

    Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue oleh Shinkichi Takamori, Taichi Matsubara, Naoki Haratake, Gouji Toyokawa, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Kenichi Taguchi, Tatsuro Okamoto, Takashi Seto

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Sarcoid‐like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab

    Sarcoid‐like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab oleh Shinkichi Takamori, Nobuki Furubayashi, Kenichi Taguchi, Taichi Matsubara, Takatoshi Fujishita, Kensaku Ito, Masafumi Yamaguchi, Ryo Toyozawa, Takashi Seto, Takahito Negishi, Motonobu Nakamura, Tatsuro Okamoto

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients

    Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients oleh Naoki Haratake, Takashi Seto, Shinkichi Takamori, Ryo Toyozawa, Kaname Nosaki, Naoko Miura, Taro Ohba, Gouji Toyokawa, Kenichi Taguchi, Masafumi Yamaguchi, Mototsugu Shimokawa, Mitsuhiro Takenoyama

    Diterbitkan 2019-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study

    Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study oleh Mototsugu Shimokawa, Kaname Nosaki, Takashi Seto, Kadoaki Ohashi, Masahiro Morise, Hidehito Horinouchi, Jun Sakakibara, Haruyasu Murakami, Seiji Yano, Miyako Satouchi, Shingo Matsumoto, Koichi Goto, Kiyotaka Yoh

    Diterbitkan 2020-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART‐1501

    S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART‐1501 oleh Minoru Fukuda, Soichiro Funaki, Takuya Yamazaki, Shuntaro Sato, Hiroshi Mukae, Mitsuhiro Takenoyama, Junya Fukuoka, Kazuki Nabeshima, Hisashi Tateyama, Kazuto Ashizawa, Masaki Hara, Takashi Seto, Meinoshin Okumura, Kenji Sugio

    Diterbitkan 2020-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Phase II study of S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART‐1501 study

    Phase II study of S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART‐1501 study oleh Minoru Fukuda, Masafumi Yamaguchi, Takuya Yamazaki, Soichiro Funaki, Hiroshi Mukae, Junya Fukuoka, Kazuki Nabeshima, Hisashi Tateyama, Kazuto Ashizawa, Noriyuki Tomiyama, Masaki Hara, Takashi Seto, Meinoshin Okumura, Kenji Sugio

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

    5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a mu... oleh Reiko Matsui, Kenichi Suzuki, Tomomi Takiguchi, Makoto Nishio, Takeshi Koike, Toshinobu Hayashi, Takashi Seto, Yuki Kogure, Naoyuki Nogami, Kimiko Fujiwara, Hiroyasu Kaneda, Tomohiko Harada, Satoru Shimizu, Masashi Kimura, Hirotsugu Kenmotsu, Mototsugu Shimokawa, Koichi Goto

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC

    Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC oleh Ryo Toyozawa, MD, Naoki Haratake, MD, PhD, Gouji Toyokawa, MD, PhD, Taichi Matsubara, MD, PhD, Shinkichi Takamori, MD, PhD, Naoko Miura, MD, Masafumi Yamaguchi, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Takashi Seto, MD, PhD

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: